Etanercept on steroid-refractary acute graft-versus-host disease

• Main Authors: Silvia González Munguía (Author), Moisés Pérez León (Author), Marta Piñero González (Author), Marina Magnolia Díaz Pestano (Author), Rafael Molero Gómez (Author), Hugo Daniel Luzardo Henríquez (Author)
• Format: Book
• Published: Elsevier, 2015-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Objetive: To describe etanercept use and effectiveness on steroid- refractary acute graft-versus-host disease after hematopoietic cell transplantation. Method: Patients treated with etanercept as off label use for steroid-refractary acute graft-versus-host disease were selected and each patient's medical history was reviewed to assess the clinical response. Results: The study included five patients: four presented with digestive manifestations and one presented pulmonary and liver manifestations. 80% of patients showed a clinical response: 60% a partial response and 20% a total response. In four cases etanercept 25mg was administered twice a week with variable duration of treatment, achieving no response in 1 case (3 weeks), partial response in two 2 cases (4 weeks and 8 weeks) and a complete response in 1 case (8 week period). Only one case was treated with etanercept 50mg administered twice a week for 5 weeks with a partial treatment response. Conclusions: The clinical response rate is consistent with the previously published data. This updates the scarce bibliographic information about etanecept use in steroid-refractary acute graft-versus-host disease. Due to clinical design limitations and the small patient population, future clinical studies should be conducted to assess the efficacy and security of etanercept in these patients.

Item Description

10.7399/fh.2015.39.3.8000
1130-6343
2171-8695